about
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them allImpacts of humanized mouse models on the investigation of HIV-1 infection: illuminating the roles of viral accessory proteins in vivoNanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV TransmissionTargeted cytotoxic therapy kills persisting HIV infected cells during ARTEfficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdAIn vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis.Tetherin/BST-2: Restriction Factor or Immunomodulator?Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.R88-APOBEC3Gm Inhibits the Replication of Both Drug-resistant Strains of HIV-1 and Viruses Produced From Latently Infected CellsDifferent modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif.HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptationAPOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model.Hypogammaglobulinemia in BLT humanized mice--an animal model of primary antibody deficiency.ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction.Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo.In vivo analysis of Nef's role in HIV-1 replication, systemic T cell activation and CD4(+) T cell loss.The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 ReplicationThe effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model.HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer.Species-specific differences in the ability of feline lentiviral Vif to degrade feline APOBEC3 proteinsAPOBEC3G-Mediated G-to-A Hypermutation of the HIV-1 Genome: The Missing Link in Antiviral Molecular MechanismsThe genetic basis for individual differences in mRNA splicing and APOBEC1 editing activity in murine macrophages.Infectious diseases in humanized mice.APOBECs and virus restriction.Humanized mice: models for evaluating NeuroHIV and cure strategies.Family-Wide Comparative Analysis of Cytidine and Methylcytidine Deamination by Eleven Human APOBEC Proteins.Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naïve chronic HIV-1 patients.HIV-1 Vpr hijacks EDD-DYRK2-DDB1DCAF1 to disrupt centrosome homeostasis.
P2860
Q26823568-30C77066-787B-4EB9-94DE-33120188A1DDQ26851152-3EF85254-FEA0-4361-93CB-614A36CA3622Q27318354-1FDE6243-7E5C-442B-87F1-9985C4406CB0Q28538598-A04981C0-0A40-4B45-A0C2-6F7FEE9B373DQ28552730-CE52E7B0-2865-460D-A2A9-84B98A98E4C9Q30009533-41810ED4-3A93-4E65-8733-23516FF0DF68Q30385433-E5AEE891-6919-4022-ABD2-21A750EF641FQ33602923-66CDCF9B-0779-426D-ACAD-4FF87B1F40EAQ33637221-CF07B9F9-DB20-4CC8-AB4A-C6FEFAF44941Q33650603-7AD19299-1AA1-43F6-873A-5BF5963BDB83Q33651576-9C3CF2EF-F37F-49FC-A21F-55B81963BCF0Q33699581-49600671-F4E7-4D8C-AEE2-05EAE46BA490Q34352429-BBD8803D-875E-40DF-A78C-BEB92CA6846AQ35291397-0C75BC23-1F06-4DA0-9174-0BA5E5C55BA1Q35579416-566F712F-4F13-4A04-9F66-852F1335F75CQ35601655-596B6068-0240-40D4-B2E8-92E8EB24E1DAQ35848314-B2FE5248-368A-470C-993A-D480E5BBDB6DQ36384317-B2E3B0E3-61D3-47CE-85E9-4EF0B8B3D965Q36811931-49E725D9-4687-4220-A2F3-4E6DE48C68FFQ37057814-B56C1F9C-E320-4788-9C76-C1A86C1D8CC3Q37300442-F3C3EBE4-FFB8-4195-8075-8C0938D8B075Q37357336-1D3DF1F7-716A-41F0-AFFC-3C80899C5639Q37512973-A8D81279-C5D7-44AE-B7F7-CD13BF152C75Q37614934-72CAC640-4EF7-42F6-91BF-8AC0198E96A1Q38126447-9FEDEB8A-01C8-4E74-B56E-A8816D7B6C10Q38394187-A6AD9EC2-0D5D-470B-87EA-8C46C1453591Q40074303-305E84F5-A44B-4A9C-AB21-6FCBB69715F2Q40212174-F95D8A1D-29D0-42D9-950E-4BD6CEEADAA6Q40705563-31234E1E-8A2A-4257-9871-0B3D63A73271Q41929461-6DC02DD7-0C96-4737-B768-27E5051C3204Q53820052-B2B3056E-92DC-469A-BFA1-9420BA24AEAC
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
HIV restriction by APOBEC3 in humanized mice.
@ast
HIV restriction by APOBEC3 in humanized mice.
@en
HIV restriction by APOBEC3 in humanized mice.
@nl
type
label
HIV restriction by APOBEC3 in humanized mice.
@ast
HIV restriction by APOBEC3 in humanized mice.
@en
HIV restriction by APOBEC3 in humanized mice.
@nl
prefLabel
HIV restriction by APOBEC3 in humanized mice.
@ast
HIV restriction by APOBEC3 in humanized mice.
@en
HIV restriction by APOBEC3 in humanized mice.
@nl
P2093
P2860
P1433
P1476
HIV restriction by APOBEC3 in humanized mice.
@en
P2093
Francisco Martinez-Torres
J Victor Garcia
John F Krisko
John L Foster
P2860
P304
P356
10.1371/JOURNAL.PPAT.1003242
P577
2013-03-28T00:00:00Z